Oseltamivir

• Description:

  Oseltamivir (GS 4104) is an orally active influenza virus neuraminidase inhibitor (NAI) . Oseltamivir inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses with mean IC50s of 0.67, 0.9, 1.34 and 13 nM, respectively[1].

• Product Name Alternative:

  GS 4104

• UNSPSC:

  12352211

• Hazard Statement:

  H315, H319, H335

• Target:

  Influenza Virus

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/oseltamivir.html

• Purity:

  99.94

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(OCC)C1=C[C@H]([C@@H]([C@H](C1)N)NC(C)=O)OC(CC)CC

• Molecular Formula:

  C16H28N2O4

• Molecular Weight:

  312.40

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]O Ferraris, et al. Sensitivity of Influenza Viruses to Zanamivir and Oseltamivir: A Study Performed on Viruses Circulating in France Prior to the Introduction of Neuraminidase Inhibitors in Clinical Practice. Antiviral Res. 2005 Oct;68 (1) :43-8.|[2]Smee DF, et al. Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice. Antiviral Res. 2016 Dec;136:45-50. |[3]Ilyushina NA, et al. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther. 2007;12 (3) :363-70. |[4]Ilyushina NA, et al. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother. 2008 Nov;52 (11) :3889-97. |[5]Smee DF, et al. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res. 2010 Oct;88 (1) :38-44.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  ACS Infect Dis. 2025 Jun 13;11 (6) :1437-1447.|Animal Model Exp Med. 2025 Jan 26.|Antiviral Res. 2016 Mar:127:68-78.|bioRxiv. 2024 Jul 7:2024.07.04.601620.|Chem Biodivers. 2024 Nov 24:e202402465.|Food Funct. 2016 Apr 20;7 (4) :2052-9. |Int J Infect Dis. 2024 Jun 27:107134.|Int J Mol Sci. 2025 Jun 3;26 (11) :5358.|NPJ Digit Med. 2025 Nov 21, 8 (1) :712.|Pharmaceuticals (Basel) . 2025 Aug 30;18 (9) :1306.|Phytochemistry. 2023 Oct:214:113829.|Phytomedicine. 2024 Jul:129:155534.|SSRN. 2024 Aug 7.|Virol Sin. 2024 Aug 19:S1995-820X (24) 00134-2.|Virology. 2024 Feb:590:109954.|Virulence. 2024 Dec;15 (1) :2301242.|Acta Pharm Sin B. 2025 May 29.|Antiviral Res. 2025 May 3:106174.|Antiviral Res. 2020 Apr;176:104751. |Arch Pharm Res. 2018 Jun;41 (6) :664-676.|Bioeng Transl Med. 2020 Dec 1;6 (1) :e10196.|Biomed Pharmacother. 2018 Jan:97:385-394.|bioRxiv. 2023 Aug 12.|bioRxiv. 2024 May 8:2024.05.06.592815.|bioRxiv. 2025 Jul 31.|Biosci Biotechnol Biochem. 2020 Apr;84 (4) :774-779.|BMC Microbiol. 2025 May 15;25 (1) :292.|Cell Prolif. 2021 Jan;54 (1) :e12953.|Chemosphere. 2015 Jul:131:41-7.|Front Cell Dev Biol. 2021 Dec 17:9:802502.|Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Transmissores de Hematozoários. 2020 Sep.|Inflammation. 2024 Feb;47 (1) :30-44.|Int J Mol Sci. 2019 Dec 12;20 (24) :6261.|Int J Mol Sci. 2022 Apr 1;23 (7) :3940.|J Ethnopharmacol. 2024 Jan 30;319 (Pt 2) :117290.|J Med Virol. 2023 Jul;95 (7) :e28968.|Lab Invest. 2020 Dec;100 (12) :1602-1617.|Sci Rep. 2021 Aug 11;11 (1) :16293.|Signal Transduct Target Ther. 2021 Apr 24;6 (1) :165.|Virol J. 2025 Jun 4;22 (1) :181.|Virology. 2020 Jun;545:1-9.|Virology. 2025 Oct:611:110642.|Viruses. 2018 Jun 13;10 (6) . pii: E325.

• CAS Number:

  [196618-13-0]